NCT01327521撤回3 期
International Randomized Study of Transarterial Chemoembolization Versus CyberKnife for Recurrent Hepatocellular Carcinoma
Albert Koong1 个研究点 分布在 1 个国家开始时间: 2011年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Freedom from local progression at 6 months and 12 months
研究概览
简要总结
Primary Objective:
To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE.
Secondary Objectives:
- To determine the progression-free survival of TACE vs. CyberKnife SBRT
- To determine the overall survival of TACE vs. CyberKnife SBRT for locally recurrent HCC
- To determine the toxicities associated with TACE or CyberKnife SBRT for the treatment of recurrent HCC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed hepatocellular carcinoma by one of the following:
- •Histopathology
- •One radiographic technique that confirms a lesion >=2 cm with arterial enhancement with washout on delayed phase
- •Hepatic lesion in patients for whom surgical resection is not possible or would not result in an opportunity for cure
- •Radiographic evidence of persistent, progressive or recurrent disease in an area previously treated with TACE. This evaluation should be determined after 6 weeks of initial TACE
- •Multi-specialty evaluation whereby the recurrent liver lesion was deemed by both the attending radiation oncologist and interventional radiologist amenable to treatment by the respective modality
- •Eligible patients must undergo an IV contrast CT scan of the liver within 6 weeks of enrollment onto the study; a contrast enhanced liver MRI may be substituted for the IV contrast CT of the liver.
- •A recent serum AFP must also be obtained within 4 weeks of enrollment.
- •Unifocal liver tumors not to exceed 7.5 cm in greatest axial dimension. Multifocal lesions will be restricted to lesions that can be treated within a single target volume within the same liver segment and to an aggregate of 7.5cm as long as the dose constraints to normal tissue can be met
- •Eastern Clinical Oncology Group performance status 0, 1 or 2
- •Patients with liver disease classified as Child Pugh class A/B; if Child's class B, score must be 8 or less
- •Albumin >= 2.5 g/dL
- •Total bilirubin <= 3 mg/dL
- •INR <= 1.5
- •Creatinine <= 2.0 mg/dL
- •Age >= 18 years old
- •Life expectancy>= 6 months
- •Ability of the research subject or authorized legal representative to understand and the willingness to sign a written informed consent document.
排除标准
- •Prior radiation for the recurrent liver tumors
- •Prior radiotherapy to the upper abdomen
- •Prior RFA to index lesion
- •Liver transplant
- •Tumors >= 7.5 cm in greatest axial dimension
- •Portal vein thrombus
- •Large varices within 2 cm of index lesion (seen on cross section imaging)
- •Contraindication to receiving radiotherapy
- •Active gastrointestinal bleed within 2 weeks of study enrollment
- •Ascites refractory to medical therapy
- •Women who are pregnant
- •Administration of any systemic chemotherapy within the last 1 month
- •Presence of multifocal lesions located in different lobes of the liver or extrahepatic metastases
- •Participation in another concurrent SYSTEMIC treatment protocol
- •Prior history of malignancy other than HCC
结局指标
主要结局
Freedom from local progression at 6 months and 12 months
时间窗: 6 months and 12 months
次要结局
- Progression-free survival(at 6, 12 and 18 months)
- Overall survival(at 6, 12, 18 months and up to 3 years)
- Serum AFP levels(1 month, 3 months, 6 months, 12 months and 18 months)
研究者
Albert Koong
Associate Professor of Radiation Oncology
Stanford University
研究点 (1)
Loading locations...
相似试验
撤回
3 期
Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)Recurrent Hepatocellular CarcinomaNCT01318200Accuray Incorporated
已完成
1 期
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular CarcinomaHepatocellular Carcinoma (HCC)NCT01247298University of Alabama at Birmingham17
Unknown
不适用
Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT02150317Eastern Hepatobiliary Surgery Hospital180
终止
3 期
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial ChemoembolizationChild-Pugh Class BRecurrent Hepatocellular CarcinomaChild-Pugh Class ANCT02762266Stanford University13
撤回
3 期
A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT02004210Seoul National University Hospital